Ricks called Indiana opting into the BALANCE model a meaningful step forward. Obesity is a serious, chronic disease, and addressing it can open the door to better health, Ricks said
(4) F Camanni, E Ghigo, and E Arvat (1998) Growth hormone-releasing peptides and their analogs Frontiers in Neuroendocrinology, 1998 Jan, Volume 19 (Issue 1), Pages 47-72
Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected
DallOglio F, Puviani M, Milani M, Micali G
Compelling results from the Phase 2B trial made headlines in December 2025, and now investors are waiting for additional data